On the stock market since 1993, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 33% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 42% below its peak. The market has trimmed its expectations for the company.
Sales run at $9.4M a year. A small number, but proof the product has real buyers.
It pays out $0.68 per share each year — regular cash for whoever holds the stock.
A loss of $13.1M against $9.4M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, BKN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BKN is a high-risk stock — not yet profitable, and its future rides on its product catching on.